Back to GALE Stock Lookup
Pages: 1 2 »» Last Page

Galena Biopharma (GALE) – Press Releases

Jun 15, 2015 07:05 AM Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress
Jun 15, 2015 07:05 AM Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress
May 28, 2015 04:10 PM Galena Biopharma to Present at the Sachs Immuno-Oncology BD&L and Investment Forum
May 28, 2015 04:10 PM Galena Biopharma to Present at the Sachs Immuno-Oncology BD&L and Investment Forum
May 27, 2015 07:05 AM Galena Biopharma Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting
May 27, 2015 07:05 AM Galena Biopharma Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting
May 22, 2015 07:05 AM Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress
May 22, 2015 07:05 AM Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress
May 7, 2015 04:15 PM Galena Biopharma Reports First Quarter 2015 Financial Results
May 7, 2015 04:15 PM Galena Biopharma Reports First Quarter 2015 Financial Results
Apr 23, 2015 07:05 AM Galena Biopharma to Report First Quarter Financial Results on Thursday, May 7, 2015
Apr 23, 2015 07:05 AM Galena Biopharma to Report First Quarter Financial Results on Thursday, May 7, 2015
Apr 14, 2015 07:21 AM Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
Apr 14, 2015 07:21 AM Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
Apr 10, 2015 11:15 AM Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million
Mar 31, 2015 07:05 AM Galena Biopharma to Present at the 14th Annual Needham Healthcare Conference
Mar 31, 2015 07:05 AM Galena Biopharma to Present at the 14th Annual Needham Healthcare Conference
Mar 26, 2015 07:05 AM Galena Biopharma Expands Patient Population in NeuVax(TM) (nelipepimut-S) and trastuzumab Phase 2b Combination Clinical Trial in HER2 1+/2+ Patients
Mar 26, 2015 07:05 AM Galena Biopharma Expands Patient Population in NeuVax(TM) (nelipepimut-S) and trastuzumab Phase 2b Combination Clinical Trial in HER2 1+/2+ Patients
Mar 18, 2015 04:35 PM Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
Mar 18, 2015 04:35 PM Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
Mar 13, 2015 09:22 AM Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
Mar 13, 2015 09:22 AM Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
Mar 12, 2015 04:01 PM Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants
Mar 12, 2015 04:01 PM Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants
Mar 3, 2015 07:05 AM Galena Biopharma to Present at the 27th Annual ROTH Conference
Feb 19, 2015 07:05 AM Galena Biopharma to Report Fourth Quarter and Year End 2014 Financial Results on Thursday, March 5, 2015
Feb 9, 2015 07:05 AM Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
Feb 5, 2015 07:05 AM Galena Biopharma Announces Orexo's Filing of a Patent Infringement Lawsuit Against Actavis Concerning Abstral(R) (fentanyl) Sublingual Tablets in the U.S.
Jan 28, 2015 07:05 AM Galena Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
Jan 20, 2015 07:05 AM Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management
Jan 15, 2015 07:05 AM Galena Biopharma to Present at the Noble Financial Capital Markets 11th Annual Investor Conference
Dec 8, 2014 07:05 AM Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
Dec 5, 2014 07:05 AM Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)
Dec 2, 2014 07:05 AM Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter
Dec 1, 2014 07:05 AM Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition
Nov 25, 2014 07:05 AM Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference
Nov 20, 2014 04:20 PM Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC
Nov 18, 2014 07:05 AM Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Nov 13, 2014 07:05 AM Galena Biopharma to Present at the Stifel 2014 Healthcare Conference
Nov 11, 2014 07:05 AM Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast C
Nov 7, 2014 07:05 AM Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting
Nov 4, 2014 07:05 AM Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014
Oct 27, 2014 07:05 AM Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014
Oct 14, 2014 07:05 AM Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan
Oct 8, 2014 07:05 AM Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(TM) (nelipepimut-S) Combination
Sep 25, 2014 04:15 PM Galena Biopharma Announces Release of Special Committee Report and Hosting of a Conference Call to Provide a Corporate Update
Sep 9, 2014 07:05 AM Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Sep 3, 2014 07:05 AM Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
Aug 21, 2014 07:05 AM Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Pages: 1 2 »» Last Page

Back to GALE Stock Lookup